{"organizations": [], "uuid": "d928791c16d3a17dfc34ab7485aa28a2b010ffbc", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-deinove-signs-license-option-agree/brief-deinove-signs-license-option-agreement-with-redx-pharma-idUSFWN1R30RA", "country": "US", "domain_rank": 408, "title": "BRIEF-Deinove Signs License Option Agreement With Redx Pharma", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-22T09:26:00.000+02:00", "replies_count": 0, "uuid": "d928791c16d3a17dfc34ab7485aa28a2b010ffbc"}, "author": "", "url": "https://www.reuters.com/article/brief-deinove-signs-license-option-agree/brief-deinove-signs-license-option-agreement-with-redx-pharma-idUSFWN1R30RA", "ord_in_thread": 0, "title": "BRIEF-Deinove Signs License Option Agreement With Redx Pharma", "locations": [], "entities": {"persons": [{"name": "deinove", "sentiment": "none"}], "locations": [], "organizations": [{"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 22, 2018 / 7:27 AM / Updated 7 minutes ago BRIEF-Deinove Signs License Option Agreement With Redx Pharma Reuters Staff March 22 (Reuters) - DEINOVE SA: * DEINOVE EXPANDS ITS INNOVATIVE ANTIBIOTIC PORTFOLIO BY SIGNING A LICENSE OPTION AGREEMENT WITH REDX PHARMA * PROGRAM DEVELOPED BY REDX PHARMA FOCUSES ON A NEW CLASS OF ANTIBIOTICS AIMED AT TREATING MOST LETHAL INFECTIONS * DEINOVE ACQUIRES AN OPTION FOR A LICENSE ON A SERIES OF MOLECULES ABOUT TO ENTER PRECLINICAL DEVELOPMENT. * REDX PHARMA ENTRUSTS DEINOVE WITH NEXT STEPS TO OPTIMIZE ITS ANTI-INFECTIVE PROGRAM. Source text for Eikon: Further company coverage: (Gdynia Newsroom)", "external_links": [], "published": "2018-03-22T09:26:00.000+02:00", "crawled": "2018-03-22T09:43:40.043+02:00", "highlightTitle": ""}